Bausch Health Companies Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Thomas J. Appio
- Full Time Employees
- 20,300
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- 2150 St. ElzEar Boulevard West Laval QC Canada H7L 4A8
- IPO Date
- Sep 20, 1994
- Website
- bauschhealth.com
- Similar Companies
- Business
- Bausch Health Companies Inc. operates as a global, diversified specialty pharmaceutical and medical device firm, dedicated to developing, manufacturing, and bringing to market a wide array of pharmaceutical, medical device, and over-the-counter offerings. The company’s core focus spans several key therapeutic areas, notably gastroenterology, hepatology, neurology, dermatology, dentistry, and medical aesthetics. Through its subsidiaries, Bausch Health conducts business across distinct operational segments, including Salix for U.S. gastrointestinal pharmaceuticals, Solta Medical for innovative medical aesthetic devices, and an International segment managing a diverse portfolio of branded and generic pharmaceutical products, OTC items, and medical devices across regions like Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Diversified Products segment further contributes with pharmaceutical offerings in areas such as neurology and other therapeutic classes, along with generic and dentistry products within the United States. In a significant strategic move, Bausch Health successfully completed the initial public offering of its eye health business, Bausch + Lomb, in May 2022, establishing it as a separately traded public entity. Bausch Health continues to hold a majority ownership interest in Bausch + Lomb, an independent company focused on vision care, surgical, and ophthalmic pharmaceutical products. Recent corporate developments include the acquisition of DURECT Corporation in September 2025, enhancing its hepatology pipeline with larsucosterol. The company, which was formerly known as Valeant Pharmaceuticals International, Inc., adopted the name Bausch Health Companies Inc. in July 2018 and maintains its global corporate headquarters in Laval, Quebec, Canada.
Company News
Bausch Health's Gastroenterology Business, Salix, to Present New Data on Cirrhosis Trends and Severe Alcohol-Associated Hepatitis at The Liver Meeting® 2026
BHC Q3 Earnings Call Highlights Raised Outlook, Xifaxan Risks
Is Bausch Health (BHC) Stock Outpacing Its Medical Peers This Year?
BHC Q3 Earnings Beat on Salix Growth, Stock Gains 9% as Outlook Rises
Bausch Health Companies Inc. (BHC) Q3 2026 Earnings Call Transcript
Bausch (BHC) Reports Q3 Earnings: What Key Metrics Have to Say
Bausch Health (BHC) Surpasses Q3 Earnings and Revenue Estimates
What Bausch Health Cos (BHC) Said on Its Q3 Earnings Call
Bausch Health Announces Full Redemption of 8.500% Senior Notes Due 2027
Bausch Health Announces US$50 Million Share Repurchase Program
BAUSCH HEALTH ANNOUNCES THIRD QUARTER 2026 RESULTS, RAISES GUIDANCE
BHC Q3 Earnings Preview: Here's What You Should Know
Analyzing Bausch Health Cos (NYSE:BHC) & Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF)
Bausch Health Cos Inc. (NYSE:BHC) Stock Has Consensus Target Price of $8.00
Bausch Health Cos (NYSE:BHC) Shares Gap Up – What’s Next?
Six-Month Pilot Study Demonstrates Improved Guideline Adherence Following Implementation of Standardized Cirrhosis Clinical Pathway
Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance
Bausch Health to Announce Third Quarter 2026 Results on October 28, 2026
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike
Consumer Confidence Falls Amid Ongoing Geopolitical Tensions: 4 Picks